Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $380 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $380.
December 14, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reaffirmed an Overweight rating on Vertex Pharmaceuticals with a steady price target of $380.
The reiteration of an Overweight rating by a reputable analyst typically signals continued confidence in the company's prospects, which can positively influence investor sentiment and potentially drive the stock price up in the short term. The maintained price target of $380 suggests that the analyst believes the stock has room to grow from its current level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100